| Literature DB >> 6273006 |
P J Dady, A P Sappino, A Rudd, I E Smith.
Abstract
Thirteen patients with small cell carcinoma of the bronchus that had become resistant to conventional chemotherapy were given 4'-(9-acridinylamino)methanesulphon-m-anisidide (mAMSA) at a dose of 90 or 120 mg/m2 at 3-week intervals. Twenty percent of the courses at 90 mg/m2 produced marked myelosuppression. No responses were observed. Median survival from the start of treatment with mAMSA was 5 weeks.Entities:
Mesh：
Substances：
Year: 1981 PMID： 6273006 DOI： 10.1007/bf00262342
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333